Gold prices just lower; monthly gains on track
Arrowhead Pharmaceuticals (NASDAQ:ARWR), based in Pasadena, California, is engaged in the development of pharmaceutical preparations. For detailed insights into ARWR's valuation and financial health metrics, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro. For detailed insights into ARWR's valuation and financial health metrics, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
Following this transaction, Olukotun retains ownership of 36,740 shares in the company. The sale was carried out under a pre-established 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks to avoid concerns about insider trading. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 6.74, though it's currently burning through cash rapidly.
Arrowhead Pharmaceuticals, based in Pasadena, California, is engaged in the development of pharmaceutical preparations.
In other recent news, Arrowhead Pharma has seen significant developments in its financial status and drug development pipeline. The company has entered into a major global license and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT), which is expected to substantially support Arrowhead's financial and developmental goals. The partnership involves a $500 million upfront payment and a $325 million common stock purchase, anticipated in 2025. This capital injection is crucial for Arrowhead, which has been quickly burning through cash, despite maintaining a healthy current ratio of 6.74.
The strategic partnership is expected to aid the commercial launch of Arrowhead's first RNA interference (RNAi) therapeutic in 2026, pending approval. Arrowhead's drug development pipeline also includes a New Drug Application with the FDA for plozasiran, a therapy targeting apolipoprotein C-III for the treatment of familial chylomicronemia syndrome. Further, Arrowhead has filed Clinical Trial Applications for ARO-INHBE and ARO-ALK7, its obesity programs, with plans to initiate Phase 1/2 studies in 2025.
Several analyst firms have weighed in on Arrowhead's prospects. H.C. Wainwright has shown confidence in Arrowhead by raising the stock's price target from $60.00 to $80.00 while maintaining a Buy rating. Meanwhile, Bernstein SocGen Group, Piper Sandler, and Citi have adjusted their price targets for Arrowhead, but maintained their respective ratings on the stock. These recent developments underscore a transformative period for Arrowhead Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.